company background image
A217730 logo

Kangstem Biotech KOSDAQ:A217730 Stock Report

Last Price

₩1.98k

Market Cap

₩111.0b

7D

-8.7%

1Y

-11.8%

Updated

24 Dec, 2024

Data

Company Financials

Kangstem Biotech Co., Ltd.

KOSDAQ:A217730 Stock Report

Market Cap: ₩111.0b

A217730 Stock Overview

A biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. More details

A217730 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Kangstem Biotech Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kangstem Biotech
Historical stock prices
Current Share Price₩1,981.00
52 Week High₩3,920.00
52 Week Low₩1,388.00
Beta0.23
1 Month Change-21.54%
3 Month Change14.05%
1 Year Change-11.76%
3 Year Change-37.90%
5 Year Change-75.66%
Change since IPO-78.84%

Recent News & Updates

Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?

Sep 24
Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?

Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?

May 24
Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?

Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) Tunnel

Mar 06
Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) Tunnel

Recent updates

Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?

Sep 24
Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?

Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?

May 24
Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?

Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) Tunnel

Mar 06
Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) Tunnel

Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?

Feb 17
Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?

Would Shareholders Who Purchased Kang Stem Biotech's (KOSDAQ:217730) Stock Three Years Be Happy With The Share price Today?

Dec 26
Would Shareholders Who Purchased Kang Stem Biotech's (KOSDAQ:217730) Stock Three Years Be Happy With The Share price Today?

Shareholder Returns

A217730KR BiotechsKR Market
7D-8.7%-4.0%-2.1%
1Y-11.8%16.1%-9.0%

Return vs Industry: A217730 underperformed the KR Biotechs industry which returned 16.1% over the past year.

Return vs Market: A217730 underperformed the KR Market which returned -9% over the past year.

Price Volatility

Is A217730's price volatile compared to industry and market?
A217730 volatility
A217730 Average Weekly Movement13.0%
Biotechs Industry Average Movement8.7%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A217730's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A217730's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
201097Jong-Cheon Nawww.kangstem.com

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration.

Kangstem Biotech Co., Ltd. Fundamentals Summary

How do Kangstem Biotech's earnings and revenue compare to its market cap?
A217730 fundamental statistics
Market cap₩111.04b
Earnings (TTM)-₩10.09b
Revenue (TTM)₩12.77b

8.7x

P/S Ratio

-11.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A217730 income statement (TTM)
Revenue₩12.77b
Cost of Revenue₩11.00b
Gross Profit₩1.78b
Other Expenses₩11.87b
Earnings-₩10.09b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-179.99
Gross Margin13.91%
Net Profit Margin-78.98%
Debt/Equity Ratio14.6%

How did A217730 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:49
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kangstem Biotech Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Changhee WooIBK Securities Co. Ltd.